People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Acurx Pharmaceuticals, LLC | — | Biotechnology | Series A | $30.1M | $13.1M | 2020 |
Katie G. Jadhon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Katie G. Jadhon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David P. Luci | 1 | 4 |
| David Luci | 1 | 3 |
| Robert Shawah | 1 | 2 |
| Robert J. DeLuccia | 1 | 2 |
| JOSEPH H. SCODARI | 1 | 1 |
| THOMAS H. HARRISON | 1 | 1 |
| JACK H. DEAN | 1 | 1 |
| Carl G. Sailer | 1 | 1 |
| Anthony G. Jadhon | 1 | 1 |
| Paul G. Baehr | 1 | 1 |
| Mark G. Rathjen | 1 | 1 |
| Michael G. Duffy | 1 | 1 |
| John G. Terrana | 1 | 1 |
| Robert DeLuccia | 1 | 1 |
| ROBERT G. SHAWAH | 1 | 1 |
| JAMES H. DONOHUE | 1 | 1 |
| CARL H. SAILER | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.